233 related articles for article (PubMed ID: 1355375)
1. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Schally AV; Redding TW
Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
[TBL] [Abstract][Full Text] [Related]
3. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
Milovanovic SR; Radulovic S; Groot K; Schally AV
Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
Szende B; Srkalovic G; Schally AV; Lapis K; Groot K
Cancer; 1990 May; 65(10):2279-90. PubMed ID: 1971771
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin.
Szende B; Lapis K; Redding TW; Srkalovic G; Schally AV
Breast Cancer Res Treat; 1989 Dec; 14(3):307-14. PubMed ID: 2575407
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
Milovanovic SR; Radulovic S; Schally AV
Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
[TBL] [Abstract][Full Text] [Related]
10. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
Szepeshazi K; Lapis K; Schally AV
Int J Cancer; 1991 Sep; 49(2):260-6. PubMed ID: 1679045
[TBL] [Abstract][Full Text] [Related]
11. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
Szende B; Zalatnai A; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1643-7. PubMed ID: 2564204
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
[TBL] [Abstract][Full Text] [Related]
13. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Fekete M; Zalatnai A; Schally AV
Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
Schally AV; Srkalovic G; Szende B; Redding TW; Janaky T; Juhasz A; Korkut E; Cai RZ; Szepeshazi K; Radulovic S
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1061-7. PubMed ID: 1981009
[TBL] [Abstract][Full Text] [Related]
15. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
Kadar T; Redding TW; Ben-David M; Schally AV
Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
[TBL] [Abstract][Full Text] [Related]
16. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.
Szepeshazi K; Schally AV; Juhasz A; Nagy A; Janaky T
Anticancer Drugs; 1992 Apr; 3(2):109-16. PubMed ID: 1388062
[TBL] [Abstract][Full Text] [Related]
17. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
Szepeshazi K; Schally AV; Halmos G; Szoke B; Groot K; Nagy A
Breast Cancer Res Treat; 1996; 40(2):129-39. PubMed ID: 8879679
[TBL] [Abstract][Full Text] [Related]
18. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
[TBL] [Abstract][Full Text] [Related]
19. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally AM; Schally AV
Breast Cancer Res Treat; 1992; 21(1):35-45. PubMed ID: 1391973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
